Stryker Corporation vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Stryker Corporation trades at $278.94 (market cap $106.24B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.46 (market cap $296.92M). The key difference: Stryker Corporation is far larger — about 357.8× YieldMax Magnificent 7 Fund of Option Income ETFs's market cap, and Stryker Corporation pays a 1.27% dividend while YieldMax Magnificent 7 Fund of Option Income ETFs pays none. Which is the better fit depends on your goals — on Pluang, investors hold Stryker Corporation for 20 Days and YieldMax Magnificent 7 Fund of Option Income ETFs for 62 Days on average.
| SYK | YMAG | |
|---|---|---|
Market Cap | $106.24B | $296.92M |
Volume | 2,982,001 | 1,023,545 |
Sector | Health | Income / Options Overlay |
52-Week High | $388.35 | $15.68 |
52-Week Low | $269.75 | $10.76 |
Typical Hold Time | 20 Days | 62 Days |
Enterprise Value | $117.70B | — |
Dividend Yield | 1.27% | — |
Signals from Pluang's Aura AI — not financial advice
Stryker (SYK) trades at $279.15, up 1.36% on the day, amid a mixed technical and fundamental backdrop. The stock shows bearish technical signals with key support at $268 and resistance at $284, while fundamentals remain solid with a 14.43% net income margin and strong analyst consensus of 71% buy ratings. Recent news highlights ongoing legal scrutiny over manufacturing issues, but the company maintains robust cash flow and earnings growth, with Q3 2026 results pending.
Outlook: SYK offers growth potential with a consensus price target of $368.11, supported by profitability and innovation, but faces near-term risks from legal investigations and technical weakness. Investors should weigh strong fundamentals against sentiment headwinds.
YMAG trades at $11.49, down 0.69% with a bullish technical signal supported by moving averages. The ETF maintains consistent weekly dividend distributions, though key valuation ratios remain unavailable. Recent news highlights ongoing distribution announcements and trading activity, with the stock showing moderate volatility within a tight $11-12 range.
The outlook remains cautiously optimistic given the bullish technical setup and income generation through dividends. However, risks include NAV stability concerns during earnings periods and dependency on underlying option strategies. Investors should weigh the high distribution yield against potential capital volatility in market downturns.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →